Commentary: Another complication associated with rhBMP-2?

Spine Journal

Volumn 11, Issue 6, 2011, Pages 517-519

  Kang, James D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TITANIUM; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BONE; BONE GRAFT; CERVICAL SPINE; CERVICAL SPINE ANTERIOR FUSION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYST; EDEMA; HEALTH CARE COST; HEMATOMA; HIP PAIN; HUMAN; ILIAC CREST BONE GRAFT; IMPLANT; INFLAMMATION; LUMBAR ANTERIOR INTERBODY FUSION; LUMBAR SPINE; MALE STERILITY; MORBIDITY; NEUROMA; NORTH AMERICA; NOTE; OSTEOLYSIS; OSWESTRY DISABILITY INDEX; OUTCOME ASSESSMENT; PATIENT CARE; PEDICLE SCREW; POSTERIOR LUMBAR INTERBODY FUSION; POSTEROLATERAL LUMBAR FUSION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROGRADE EJACULATION; RISK; SHORT FORM 36; SOFT TISSUE; SPINE SURGERY; SURGEON; UNITED STATES; WOUND INFECTION; CHEMICALLY INDUCED DISORDER; MALE; METHODOLOGY; POSTOPERATIVE COMPLICATION; SEXUAL DYSFUNCTION; SPINE FUSION;

BONE MORPHOGENETIC PROTEIN 2; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79959935052     PISSN: 15299430     EISSN: 18781632     Source Type: Journal    
DOI: 10.1016/j.spinee.2011.03.022     Document Type: Note

References (22)

1. E.J. Carragee, K.A. Mitsunaga, E.L. Hurwitz, and G.J. Scuderi Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study Spine J 11 2011 511 516
2. T. Mroz, T. Yamashita, and I. Lieberman The on- and off-label use of rhBMP-2 (INFUSE) in Medicare and non-Medicare patients Spine J 8 2008 41S 42S
3. M.D. Helgeson, R.A. Lehman, and J.C. Patzkowski Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion Spine J 11 2011 507 510
4. P. Klimo Jr., and M.W. Peelle Use of polyetheretherketone spacer and recombinant human bone morphogenetic protein-2 in the cervical spine: a radiographic analysis Spine J 9 2009 959 966
5. J.B. Knox, J.M. Dai, and J. Orchowski Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2 Spine 36 2011 672 676
6. R.J. Mannion, A.M. Nowitzke, and M.J. Wood Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2 - but what is the cost? Spine J 11 2011 527 533
7. T.E. Mroz, J.C. Wang, R. Hashimoto, and D.C. Norvell Complications related to osteobiologics use in spine surgery: a systematic review Spine 35 9 Suppl 2010 S86 S104
8. B. Perri, M. Cooper, C. Lauryssen, and N. Anand Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion: a case study Spine J 7 2007 235 239
9. J.A. Rihn, R. Patel, and J. Makda Complications associated with single-level transforaminal lumbar interbody fusion Spine J 9 2009 623 629
10. T. Smoljanovic, and M. Pecina Re: Burkus J K, Sandhu H S, Gornet M F. Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft. Spine 2006;31:775-81 Spine 33 2008 226
11. T. Smoljanovic, F. Siric, and I. Bojanic Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2 J Bone Joint Surg Am 92 2010 2614 2615 author reply 2615-6
12. J.D. Smucker, J.M. Rhee, and K. Singh Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine Spine 31 2006 2813 2819 (Pubitemid 44772783)
13. L.M. Tumialán, and G.E. Rodts Adverse swelling associated with use of rh-BMP-2 in anterior cervical discectomy and fusion Spine J 7 2007 509 510
14. R. Vaidya, R. Weir, and A. Sethi Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence J Bone Joint Surg Br 89 2007 342 345 (Pubitemid 46563910)
15. B.J. Williams, J.S. Smith, and K. Fu Complications associated with BMP use in 11,933 cases of spinal fusion Spine J 10 9 Suppl 1 2010 S98 S99
16. D.A. Wong, A. Kumar, and S. Jatana Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2) Spine J 8 2008 1011 1018
17. C. Papakostidis, G. Kontakis, M. Bhandari, and P.V. Giannoudis Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results Spine 33 2008 E680 E692
18. J.R. Dimar, S.D. Glassman, K.J. Burkus, and L.Y. Carreon Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft Spine 31 2006 2534 2540
19. L.Y. Carreon, S.D. Glassman, and M. Djurasovic RhBMP-2 versus iliac crest bone graft for lumbar spine fusion in patients over 60 years of age: a cost-utility study Spine 34 2009 238 243
20. B.I. Martin, S.K. Mirza, and B.A. Comstock Are lumbar spine reoperation rates falling with greater use of fusion surgery and new surgical technology? Spine 32 2007 2119 2126 (Pubitemid 47359619)
21. United States Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health InFUSE bone Graft/LT-CAGE? Lumbar Tapered fusion Devices - P000058. 2002 Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm? num5P000058 Accessed January 20, 2011
22. R.V. Shah, T.J. Albert, and V. Bruegel-Sanchez Industry support and correlation to study outcome for papers published in Spine Spine 30 2005 1099 1104 (Pubitemid 40663920)